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A recentCell paper byHe et al. (2009) shows howmetformin circumvents a block between insulin and atypical
protein kinase C in obese and diabetic mice to inhibit gluconeogenesis by stimulating the phosphorylation of
CBP and the disassembly of the CREB transcriptional complex.Type 2 diabetes is a complex systemic
disease that involves multiple organs and
dysregulates glucose and lipid metabo-
lism while provoking life-threatening
sequelae. Hepatic insulin resistance is
especially (Ide et al., 2004) important in
type 2 diabetes as it exacerbates fasting
glucose concentrations and diminishes
postprandial glucose tolerance (Edgerton
et al., 2009). While compensatory hyperin-
sulinemia can prevent full-blown diabetes,
the insulin-resistant liver produces excess
triglyceride and cholesterol that prog-
resses to systemic dyslipidemia, nonalco-
holic fatty liver disease (NAFLD), and
obesity (Postic and Girard, 2008). How
insulin resistance leads to both hypergly-
cemia and hyperlipidemia is a complex
question of immense clinical importance.
Treatments for fatty liver disease are
poorly established, but drugs that improve
hepatic insulin sensitivity and glucose
tolerance—including metformin (N,N-di-
methylimidodicarbonimidic diamide), the
thiazolidinediones, insulin secretagogues,
and dipeptidyl peptidase-4 inhibitors—
can be beneficial (Edgerton et al., 2009;
Postic and Girard, 2008). In the May 15th
issue of Cell, He et al. bring us closer to
understanding how metformin can bypass
the block in a poorly defined branch of the
hepatic insulin signaling cascade to treat
hyperglycemia in obese and insulin-
resistant mice (He et al., 2009).
Metformin is a first-line treatment for
type 2 diabetes because it can reduce by
more than 30% hepatic glucose produc-
tion and improve insulin sensitivity in
typical type 2 diabetic patients (Edgerton
et al., 2009). Metformin is especially effec-
tive in obese and insulin-resistant patients
and might have beneficial effects upon
cardiac function (Eurich et al., 2007). Met-
formin was first used in Europe over 40
years ago, but since 1995 it has becomeone of the top 10 most prescribed drugs
in the United States (http://drugtopics.
modernmedicine.com/drugtopics/data/
articlestandard//drugtopics/192009/
597084/article.pdf). Like many other anti-
diabetic drugs, metformin was used clini-
cally long before its mechanism of action
was understood. Most rodent experiments
showthatmetformin inhibitshepatic gluco-
neogenesis; however, data in humans are
not definitive on this point (Edgerton et al.,
2009). Regardless, the beneficial effects
of metformin upon glucose metabolism
in humans are clear, so a better under-
standing of metformin action might
presage better treatments for type 2 dia-
betes.
About 8 years ago metformin was
shown to stimulate the AMP-activated
protein kinase (AMPK) (Zhou et al., 2001).
AMPK is expressed in all eukaryotic cells
where it is activated by STK11 (serine/
threonine kinase 11, or LKB1) -mediated
phosphorylation that is engaged physio-
logically by an increasing AMP:ATP ratio
or pharmacologically by drugs like AICAR
(aminoimidazole carboxamide ribonucle-
otide) or metformin (Shaw et al., 2005).
Insulin and AMPK signaling are frequently
regulated in opposite directions; however,
for glucose metabolism, insulin and AMPK
signaling pathways tend to work in the
same direction. So how can insulin and
metformin have similar effects upon
hepatic metabolism? Part of the mecha-
nism appears to involve the inactivation
of a glucagon-stimulated nuclear tran-
scription complex assembled from
CREB (cAMP response element-binding
protein), CBP (CREB-binding protein),
and CRTC2 (CREB-regulated transcrip-
tion coactivator 2) (Figure 1). During star-
vation, glucagon promotes the assembly
of the transcriptionally active CREB-
CBP-CRTC2 complex, which increasesCell Metabolthe expression of Ppargc1a (peroxisome
proliferator-activated receptor-g coacti-
vator-1) and other key hepatic genes
needed for gluconeogenesis, including
Pck1 (phosphoenolpyruvate carboxyki-
nase) and G6pase (glucose-6-phospha-
tase) (Ravnskjaer et al., 2007). However,
during the postprandial period, activation
of the PI3 kinase/AKT (v-akt murine thy-
moma viral oncogene) cascade by insulin
stimulates SIK2 (salt-inducible kinase 2),
which inactivates the CREB-CBP-CRTC2
complex by phosphorylating CRTC2 at
Ser171 and targeting it for degradation in
the cytosol (Figure 1) (Dentin et al., 2007).
Remarkably, metformin also stimulates
the phosphorylation of CRTC2 at Ser171,
promoting its nuclear exclusion and
revealing a mechanism to explain the
convergent effect of insulin and metformin
upon the inhibition of hepatic gluconeo-
genesis—except for one thing: CRTC2 is
O-glycosylated at Ser171 during obesity
and insulin resistance completely blocking
metformin-stimulated phosphorylation
when it is needed the most (Dentin et al.,
2008). So phosphorylation of CRTC2 at
Ser171 is unlikely to be the path used by
metformin to circumvent insulin resis-
tance in diabetic patients.
Troubled by the realization that Ser171
phosphorylation of CRTC2 could not
explain the antidiabetic properties of met-
formin, He et al. found another mecha-
nism by which insulin and metformin can
disrupt the active CREB-CBP-CRTC2
complex. Only this time, metformin works
well during obesity and insulin resistance
when it is needed the most (He et al.,
2009). They show how insulin and metfor-
min activate aPKCi/l (atypical protein
kinase C), which phosphorylates CBP
at Ser436 to initiate the disassembly of
the CBP:CRTC2 dimer from CREB (Fig-
ure 1). This idea is important because itism 9, June 3, 2009 ª2009 Elsevier Inc. 485
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PreviewsFigure 1. Insulin and Metformin Signaling to aPKC in Liver
Elements of the IRS2 branch of the insulin signaling cascade are shaded gray, whereas elements of the IRS1 branch of the cascade are not shaded. IRS1 and
IRS2 play a common role in the activation of the PI3 kinase/[PDK1/AKT]/FOXO cascade. The IRS2/PI3 kinase/[PDK1/aPKCi/l]/CBP cascade inac-
tivates the CREB:CBP:CRTC2 transcription complex. Metformin also activates aPKCi/l through a different mechanism, which circumvents hepatic insulin resis-
tance to phosphorylate CBP and inactivate the CREB:CBP:CRTC2 transcription complex, especially during hepatic insulin resistance associated with obesity
and type 2 diabetes. Phosphorylation sites (pS or pY) highlighted in green indicate activation steps, whereas sites highlighted in red indicate inhibitory steps.demonstrates how metformin—an antidi-
abetic drug that improves glucose
homeostasis—can circumvent the block
imposed by insulin resistance and activate
a common signaling intermediate that
reduces the expression of gluconeogenic
enzymes under conditions of obesity,
insulin resistance, and hyperglycemia.
Hepatic insulin signaling is mediated by
tyrosine phosphorylation of IRS1 (insulin
receptor substrate 1) and IRS2, and both
substrates activate the PI3 kinase/AKT
cascade to inhibit nuclear FOXO1 (fork-
head box O1) transcriptional activity.
This cascade is important because
nuclear FOXO stimulates strongly the
expression of Ppargc1a and the gluco-
neogenic genes. However, the CREB-
CBP-CRTC2 complex also needs to be
inactivated by aPKC-mediated phosphor-
ylation of CBP, which during insulin stimu-
lation might occur exclusively through the
IRS2 branch of the pathway (Farese et al.,486 Cell Metabolism 9, June 3, 2009 ª20092005). How this signaling specificity arises
is unknown. Regardless, this specificity is
probably very important because IRS2
expression is ordinarily augmented during
starvation by CREB-CBP-CRTC2 itself,
FOXO1, and TFE3 (transcription factor
E3), which should increase basal insulin
signaling and attenuate fasting gluconeo-
genesis. Moreover, this mechanism can
prepare hepatocytes to shut down post-
prandial gluconeogenesis quickly and
with minimal insulin stimulation. However,
nutrient excess and compensatory
hyperinsulinemia preferentially suppress
hepatic IRS2 expression, at least in part,
by sustained IRS1 signaling that increases
the expression of SREBP1c—an impor-
tant transcriptional regulator of lipid
synthesis that also blocks IRS2 expres-
sion (Ide et al., 2004). This mechanism is
expected to prevent insulin-stimulated
CBP phosphorylation, while the ensuing
compensatory hyperinsulinemia stimu-Elsevier Inc.lates the IRS1 branch of the insulin
signaling cascade to sustain SREBP1c
expression and promote triglyceride
synthesis. Although more work is needed
to reveal and validate all the aspects of
this mechanism, by activating aPKCi/l
with metformin the insulin requirement
should fall, along with gluconeogenesis,
hepatic insulin resistance, and triglyceride
synthesis (Figure 1). Although metformin
might not be the most efficacious drug
for this job, the convergent signaling
cascade should be a valuable framework
to identify more robust compounds to
treat type 2 diabetes.
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The characterization of genetic and exper-
imental syndromes of obesity in rodents
has played a major role in the identification
of the molecular components of energy
homeostasis over the last 15 years (Fried-
man, 2004). The finding that mutations in
many of these genes result in severe
obesity in humans has demonstrated
that these pathways, in particular the lep-
tin-melanocortin pathway, are highly
conserved across mammalian species.
There are a number of human genetic
syndromes where obesity occurs in asso-
ciation with developmental delay and
organ-specific abnormalities. In many
cases, significant progress has been
made in understanding the molecular
and cellular mechanisms underlying these
complex syndromes (for example in Bar-
det-Biedl Syndrome), but the mecha-
nisms whereby mutations in these specific
genes lead to obesity are only beginning to
emerge.
One such disorder is Albright hereditary
osteodystrophy (AHO). First described by
the American Endocrinologist Fuller Al-
bright in 1942, the characteristic features
are obesity, short stature, skeletal defects,
and subcutaneous calcification. AHO is an
autosomal dominantdisorder due to germ-
line mutations in the GNAS1 gene thatHe, L., Sabet, A., Djedjos, S., Miller, R., Sun, X.,
Hussain, M.A., Radovick, S., and Wondisford,
F.E. (2009). Cell 137, 635–646.
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829–838.’s All About the Pa
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the GNAS1 gene is associated with
sue, Chen et al. (2009) have generate
lele to trace the origin of the phenoty
decrease expression or function of Gsa
protein, which couples seven-transmem-
brane domain receptors to the cAMP-
generating enzyme adenylyl cyclase.
Several groups have shown that imprinting
plays a role in the pathogenesis of AHO
(Davies and Hughes, 1993), as the pres-
ence or absence of another phenotype,
multihormone resistance, in an affected
individual is determined by whether the
disease is inherited from the father or the
mother (Weinstein et al., 2002) (Figure 1).
Thus, patients who inherit the mutation
from their father develop AHO, whereas
patients who inherit the mutation from their
mother develop AHO and resistance to
a number of hormones including parathy-
roid hormone and thyroid stimulating
hormone.
Imprinting is an epigenetic phenomenon
affecting a small number of genes whereby
transcriptional silencing of one allele
(paternal or maternal depending on the
specific gene) results in partial or total
loss of expression. Differences in DNA
methylation appear to be critical in
both the initiation and maintenance of
imprinting. Gsa is imprinted in a tissue-
specific and developmental stage-specific
manner and expressed primarily from the
maternal allele in various hormone target
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obesity in humans, but the mecha-
d mice with brain specific deletion
pe.
tissues. Maternal inheritance of GNAS1
mutations results in obesity and multihor-
mone resistance in humans, and knockout
of the maternal allele results in mice that
are obese with reduced sympathetic
nervous system (SNS) activity and energy
expenditure.
In this issue of Cell Metabolism, Wein-
stein and colleagues investigated whether
Gsa imprinting in the CNS accounts for
these parent-of-origin metabolic effects,
by generating mice with CNS-specific
disruption of the maternal (mBrGsKO) or
paternal (pBrGsKO) Gsa allele. Female
mice with loxP sites surrounding Gsa
exon 1 were mated with nestin-cre males
(which express cre recombinase in the
CNS) to generate mBrGsKO mice;
pBrGsKO mice were generated with recip-
rocal crosses. mBrGsKO mice gained
much more weight than controls after
6 weeks with an increase in fat mass,
whereas pBrGsKO showed no differences
in body weight or composition. In a series
of elegant experiments, the authors
showed that the weight gain was predom-
inantly attributable to reduced resting and
total energy expenditure (TEE) (normalized
for body weight) at ambient temperatures
(21C or 23C). In both males and females,
linear regressions of body weight versus
sm 9, June 3, 2009 ª2009 Elsevier Inc. 487
